146 related articles for article (PubMed ID: 6230989)
1. In vitro susceptibility of human and environmental isolates of Mycobacterium avium, M. intracellulare, and M. scrofulaceum to heavy-metal salts and oxyanions.
Falkinham JO; George KL; Parker BC; Gruft H
Antimicrob Agents Chemother; 1984 Jan; 25(1):137-9. PubMed ID: 6230989
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology of infection by nontuberculous mycobacteria. VI. Identification and use of epidemiologic markers for studies of Mycobacterium avium, M. intracellulare, and M. scrofulaceum.
Fry KL; Meissner PS; Falkinham JO
Am Rev Respir Dis; 1986 Jul; 134(1):39-43. PubMed ID: 3729160
[TBL] [Abstract][Full Text] [Related]
3. Susceptibilities of Mycobacterium fortuitum biovariant fortuitum and the unnamed third biovariant complex to heavy-metal salts.
Wallace RJ; Steele LC; Forrester GD; Swenson JM; Hull SI
Antimicrob Agents Chemother; 1984 Oct; 26(4):594-6. PubMed ID: 6517549
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of intra- and extracellular Mycobacterium avium-intracellulare to cephem antibiotics.
Nozawa RT; Kato H; Yokota T; Sugi H
Antimicrob Agents Chemother; 1985 Jan; 27(1):132-4. PubMed ID: 3985594
[TBL] [Abstract][Full Text] [Related]
5. Activity of ciprofloxacin against Mycobacteria in vitro: comparison of BACTEC and macrobroth dilution methods.
Trimble KA; Clark RB; Sanders WE; Frankel JW; Cacciatore R; Valdez H
J Antimicrob Chemother; 1987 May; 19(5):617-22. PubMed ID: 3112096
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of four fluoroquinolones against eighty-six isolates of mycobacteria.
Texier-Maugein J; Mormède M; Fourche J; Bébéar C
Eur J Clin Microbiol; 1987 Oct; 6(5):584-6. PubMed ID: 3125050
[TBL] [Abstract][Full Text] [Related]
7. Specificity and distribution of alpha antigens of Mycobacterium avium-intracellulare, Mycobacterium scrofulaceum, and related species of mycobacteria.
Tasaka H; Nomura T; Matsuo Y
Am Rev Respir Dis; 1985 Jul; 132(1):173-4. PubMed ID: 2409853
[TBL] [Abstract][Full Text] [Related]
8. Plasmid DNA profiles as epidemiological markers for clinical and environmental isolates of Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium scrofulaceum.
Meissner PS; Falkinham JO
J Infect Dis; 1986 Feb; 153(2):325-31. PubMed ID: 3944484
[TBL] [Abstract][Full Text] [Related]
9. Activity of five fluoroquinolones against Mycobacterium avium-intracellulare complex and M. xenopi.
Rastogi N; Goh KS; David HL
Ann Inst Pasteur Microbiol; 1988; 139(2):233-7. PubMed ID: 3165641
[No Abstract] [Full Text] [Related]
10. Selective medium for the isolation and enumeration of Mycobacterium avium-intracellulare and M. scrofulaceum.
George KL; Falkinham JO
Can J Microbiol; 1986 Jan; 32(1):10-4. PubMed ID: 3697842
[TBL] [Abstract][Full Text] [Related]
11. Mycobacterial plasmids: screening and possible relationship to antibiotic resistance in Mycobacterium avium/Mycobacterium intracellulare.
Franzblau SG; Takeda T; Nakamura M
Microbiol Immunol; 1986; 30(9):903-7. PubMed ID: 3540539
[No Abstract] [Full Text] [Related]
12. Isolation of the Mycobacterium avium-M. intracellulare-M. scrofulaceum complex from tank water in Queensland, Australia.
Tuffley RE; Holbeche JD
Appl Environ Microbiol; 1980 Jan; 39(1):48-53. PubMed ID: 7356321
[TBL] [Abstract][Full Text] [Related]
13. Use of the BACTEC system for drug susceptibility testing of Mycobacterium tuberculosis, M. kansasii, and M. avium complex.
Steadham JE; Stall SK; Simmank JL
Diagn Microbiol Infect Dis; 1985 Jan; 3(1):33-40. PubMed ID: 3917885
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of opportunist mycobacteria to rifampicin and ethambutol.
Yates MD; Collins CH
Tubercle; 1981 Jun; 62(2):117-21. PubMed ID: 7303160
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria.
Tomioka H; Sato K; Saito H
Tubercle; 1991 Sep; 72(3):176-80. PubMed ID: 1771676
[TBL] [Abstract][Full Text] [Related]
16. [In vitro activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis, M. avium, M. africanum, M. kansasii and BCG strains].
Thomas L; Naumann P; Crea A
Immun Infekt; 1986 Nov; 14(6):203-7. PubMed ID: 3100424
[TBL] [Abstract][Full Text] [Related]
17. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
Cho EH; Huh HJ; Song DJ; Moon SM; Lee SH; Shin SY; Kim CK; Ki CS; Koh WJ; Lee NY
J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615
[TBL] [Abstract][Full Text] [Related]
18. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China.
Zhang Z; Pang Y; Wang Y; Cohen C; Zhao Y; Liu C
Int J Antimicrob Agents; 2015 May; 45(5):491-5. PubMed ID: 25795316
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of quinolones and macrolides against mycobacteria.
Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF
J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409
[TBL] [Abstract][Full Text] [Related]
20. Difference in drug susceptibility distribution and clinical characteristics between
Wang W; Yang J; Wu X; Wan B; Wang H; Yu F; Guo Y
J Med Microbiol; 2021 May; 70(5):. PubMed ID: 33999797
[No Abstract] [Full Text] [Related]
[Next] [New Search]
